Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Develop Assay as CDx for Ferring's Infertility Treatment

NEW YORK (GenomeWeb) – Roche will develop an existing assay as a companion diagnostic for Ferring Pharmaceuticals' potential infertility treatment under a deal announced today.

Roche will qualify, validate, document, and seek regulatory approval for its test, the Elecsys AMH assay, for use in combination with Ferring's human cell line-derived recombinant follicle-stimulating hormone, a gonadotrophin in phase III development. The Elecsys AMH assay evaluates anti-Müllerian hormone levels, a measure of a woman's ovarian reserve and her response to infertility treatment with gonadotrophin, Roche and Ferring said.

The assay runs on Roche's cobas electrochemiluminescence immunoassay platform and takes about 18 minutes to produce results, compared to several hours with manual AMH testing, they added. The test would allow physicians to personalize dosing of Ferring's treatment and could improve the predictability of infertility treatment, lowering the burden of treatment for women using assisted reproductive technology for conception.

Financial and other terms of the deal were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.